Seres Therapeutics (MCRB) Invested Capital: 2015-2025
Historic Invested Capital for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $43.7 million.
- Seres Therapeutics' Invested Capital rose 82.69% to $43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.7 million, marking a year-over-year increase of 82.69%. This contributed to the annual value of $13.8 million for FY2024, which is 130.73% up from last year.
- Per Seres Therapeutics' latest filing, its Invested Capital stood at $43.7 million for Q3 2025, which was up 32.62% from $33.0 million recorded in Q2 2025.
- Seres Therapeutics' 5-year Invested Capital high stood at $175.7 million for Q3 2021, and its period low was -$87.1 million during Q2 2024.
- Over the past 3 years, Seres Therapeutics' median Invested Capital value was $13.8 million (recorded in 2024), while the average stood at -$6.1 million.
- Its Invested Capital has fluctuated over the past 5 years, first soared by 333.10% in 2021, then tumbled by 515.99% in 2023.
- Over the past 5 years, Seres Therapeutics' Invested Capital (Quarterly) stood at $131.5 million in 2021, then plummeted by 91.80% to $10.8 million in 2022, then plummeted by 515.99% to -$44.9 million in 2023, then surged by 130.73% to $13.8 million in 2024, then spiked by 82.69% to $43.7 million in 2025.
- Its Invested Capital stands at $43.7 million for Q3 2025, versus $33.0 million for Q2 2025 and $50.5 million for Q1 2025.